Optimism that the FOMC verdict over rates due this evening may be kind to markets has failed to materialise, with Wall Street futures giving back earlier gains and London’s AIM Index tracking sideways, finishing the day just a fraction of a point lower at 827.96.
- Mirriad Advertising +377%
- Fusion Antibodies +22%
- Braveheart Investment Group +21%
- Solgenics -68%
- Versarien -44%
Mirriad Advertising LON:MIRI saw its shares surge by an eye-catching 377% today following news of a tie up with Microsoft. This offers the company a much needed boost, with shares having fallen from 63p two years ago to around the 1p mark last week.
Fusion Antibodies LON:FAB added a rather more modest 22% on the day, putting the stock in second place but that was barely above the spread and volumes appeared to be far from exceptional, suggesting that the move may be more down to a lack of liquidity.
Braveheart LON:BRH gets the notable mention, up 21% on Wednesday’s trade. The company provided an update on the performance of its investments this morning, with two portfolio constituents now making the progress which investors have been waiting some time for.
Solgenics [LON:SGN] was the biggest faller, off 68% at the bell after the company became the latest in a long line to suggest a delisting, noting that the requirements to remain on AIM were disproportionate to the benefits this offered.
- Three Quick Facts: Next, Mirriad, Serica Energy
- Three Quick Facts: Tullow, Chapel Down, Versarien
- Small Cap Stocks: Rockfire Resources, Fusion Antibodies, Oracle Power
Versarien LON:VRS fell 44% in the wake of news that it had raised just over £500k at a meaningful discount, along with an update on its turnaround strategy. Detail here is limited, but the company has promised further updates in the coming weeks.
